



IDenta Corporation (OTCQB: IDTA)

State of Incorporation: Florida

SIC Code: 9711

www.identa-corp.com

Annual Report

For the period ending December 31, 2023

(the "Reporting Period")

The number of shares outstanding of our Common Stock is 4,045,589 as of December 31, 2022

The number of shares outstanding of our Common Stock was 4,045,589 as of December 31, 2023

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a change in control of the company has occurred over this reporting period:

Yes: ☐ No: ☒

TABLE OF CONTENT

ITEMS	DESCRIPTIONS	PAGES
Items 1 - 2	Exact Name of the Issuer and the Address of its Principal Executive Offices	3
Item 3	The Jurisdiction(s) and Date of the Issuer's Incorporation or Organization	4
Item 4	The Exact Title and Class of Securities Outstanding.	4
Item 5	Par or Stated Value and Description of the Security	4
Item 6	Shares Outstanding	4
Item 7	The Name and Address of the Transfer Agent	4
Item 8	The Nature of the Issuer's Business	5 – 6
Item 9	The Nature of Products or Services Offered	6 – 11
Item 10	The Nature and Extent of the Issuer's Facilities.	11
Item 11	The name of the CEO, Board of Directors and Control Persons	12 – 13
Item 12	Financial Information for the Issuer's Most Recent Fiscal Period	14 – 28
Item 13	Similar Financial Information for Such Part of the Two Preceding Fiscal Years as the Issuer or its Predecessor has been in Existence	29
Item 14	Beneficial Owners	29
Item 15	Outside Providers that Advise the Issuer on Matters Relating to Operations, Business Development and Disclosure	29
Item 16	Management's Discussion and Analysis of Plan of Operation	30 – 32
Item 17	List of Securities Offerings and Shares Issued for Services in the Past Two Years	33
Item 18	Material Contracts	33 – 34
Item 19	Articles of Incorporation and Bylaws	34
Item 20	Purchases of Equity Securities by the Issuer and Affiliated Purchasers	35
Item 21	Certifications	35

FORWARD-LOOKING STATEMENTS

Certain statements made in this Quarterly Report are “forward-looking statements” regarding the plans and objectives of management for future operations and market trends and expectations. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved.

These forward-looking statements rely on assumptions, estimates and predictions that could be inaccurate and that are subject to risks and uncertainties that could cause actual results to differ materially from expected results. We cannot guarantee future results, outcomes, levels of activity, performance, or achievements, and there can be no assurance that our expectations, intentions, anticipations, beliefs, or projections will result or be achieved or accomplished. Forward-looking statements speak only as of the date of this report. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements, or to update the reasons actual results could differ significantly from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Part A: General Company Information

Items 1: The Exact Name of the Issuer

IDenta Corporation

Items 2: The Address of its Principal Executive Offices

Government Site: www.identa-corp.com Consumer Site: www.touch-know.com Consumer Site: www.getswipper.com	3501 Keyser Avenue, Suite 22 Hollywood, FL 33021, USA Tel: (240) 545-6646
	120 Bethlehem Road Jerusalem 9342001, Israel Tel: +972.2.587.2220

Items 3: The Jurisdiction(s) and Date of the Issuer's Incorporation or Organization

January 30, 2002. Florida Corporation

Part B: Share Structure**Item 4: The Exact Title and Class of Securities Outstanding**

Trading Symbol: IDTA

Exact title and class of securities outstanding: Common Stock

CUSIP: 451671200

Item 5: Par or Stated Value and Description of the Security

A. Par or Stated Value: \$0.001

B. Common Stock

Item 6: Shares Outstanding

The following tables sets forth the number of shares outstanding for each class of securities authorized as of the dates set forth below:

COMMON STOCK	
Period Number of Shares Authorized	DECEMBER 31, 2023
Number of Shares Authorized	16,400,000,000
Number of Shares Outstanding	4,045,589
Freely Tradable Shares (Public Float)	2,283,491
Number of Beneficial Shareholders Owning at Least 100 Shares	149
Total Number of Stockholders of Record	172

Item 7: The Name and Address of the Transfer Agent

Name: Issuer Direct Corporation

Phone: +1.919.343.9941

Registered under the exchange act: Yes

Address: One Glenwood Ave, Raleigh, NC 27603, NC 27603, USA

Part C: Business Information

Item 8: The Nature of the Issuer's Business

A. Business Development

1. The form of organization of the issuer: Corporation.
2. The year that the issuer was organized: 2002.
3. The issuer's fiscal year end date: December 31.
4. Whether the issuer (or any predecessor) has been in bankruptcy, receivership, or any similar proceeding: No.
5. Any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets: No.
6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments: No.
7. Any change of control: No.
8. Any increase of 10% or more of the same class of outstanding equity securities: No.
9. Any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization: Past – Stock Split.
10. Any delisting of the issuer's securities by any securities exchange: No.
11. Any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations and any current, past or pending trading suspensions by a securities regulator. State the names of the principal parties, the nature and current status of the matters, and the amounts involved: No.

B. Business of Issuer

1. The issuer's primary and secondary SIC Codes: 9711
2. The issuer is currently conducting operations:
The issuer has a full production line of all products. There are automatic and semi-automatic machines. It is possible to adjust new products and models in advanced development stages in order to optimize the rate and production capacity.
3. Whether the issuer has at any time been a "shell company": No
4. The names and contact information of any parent, subsidiary, or affiliate of the issuer, and its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure statement: The Company has a subsidiary called IDenta Ltd, owned 100% by the issuer. The financial statements of the issuer include the subsidiary. The

subsidiary develops, manufacture and sell Drugs & Explosives on time use detection kits and additional unique forensic products.

5. The effect of existing or probable governmental regulations on the business:

The products should have a government lab confirmation to be able to sell in the country.

6. An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities were borne directly by customers:

The issuer spent a couple tens of thousands dollars in each of the last years in patents, moldings, innovation molds and specific solutions for targeted customers.

7. Costs and effects of compliance with environmental laws (federal, state and local);

The products are adapted to laws environmental standards.

8. The number of total employees and number of full-time employees.

Total of 25 employees, 15 of them in full-time.

Item 9: The Nature of Products or Services Offered

A. Principal Products and their Markets

Drug Detection Kits

The Company has developed and manufactures a novel and unique Drug Detector Field Test Kit commonly known as a "Touch&Know." The Touch&Know is a chemical device used to instantly identify different kinds of illicit drugs, including Marijuana/hashish, Cocaine/Crack, Brown and White Heroin, Ecstasy-MDMA, MDA, Amphetamine and Methamphetamine (Crystal meth), LSD, Morphine, Ketamine, GHB, Bath salt, and Synthetic Cannabinoids. The Company believes that its technology can detect all known illicit drugs described in current literature. In addition, in the event that new substances become controlled, regulated or banned, the Company anticipates that it will be able to adapt its kits or create new solutions to indicate the presence of those substances.

The Company's products were primarily developed by Mr. Baruch Glattstein, the Company's Chief Science Officer. Mr. Glattstein is a former chief scientist of the Israeli Police forensic department and has over three decades of relevant industry experience. Following years of testing and research and the development of first-generation solutions, Mr. Glattstein developed a new and unique and versatile General Drug Screening Kit with advanced chemistry capable of providing a positive response for 21 types of known drugs with a high degree of accuracy.

Our Touch&Know provide immediate results which enable both law enforcement and consumers to determine whether or not a particular substance is an illegal drug.

Our tests involve a user breaking up to three ampules safely embedded within a sealed plastic device according to clear instructions. No special training is required. The Company believes that its products have several important advantages over competing products.

- Their accuracy provides a significant advantage particularly to law enforcement individuals as a reliable basis for impoundment or arrest until definitive lab tests are available.
- Our drug detector kits involve one or two simple steps to test for most narcotics, or three steps in the case of plant-based narcotics.
- Our Touch&Know preserve the integrity of the suspicious substance in a sealed container which can be submitted for further lab testing to provide evidence which is admissible in court. Competing solutions do not isolate the questionable substance for contamination and the field test itself renders the substance unusable for laboratory tests. This requires reliance on a separate sample to be sent to a lab.
- Our proprietary Smart Tip Probe™ enables users to easily collect specimens enabling the tester to avoid contact with questionable and potentially hazardous substances, in contrast with competing products which require a more complicated and potentially messy collection process.
- Chemical reactions occur in a closed plastic unit with our proprietary No-Spill Seal™ which avoids the need for contact with chemicals, and our kits include a built-in process to neutralize powerful acids. Competing kits expose testers to contact with potentially hazardous chemicals.
- Our kits are inexpensive and to our knowledge, we are the only providers of retail solutions to consumers which are available for an affordable price.
- The company has a unique Drugs General Screening Kit to identify 24 types of drugs in one kit.
- We believe that we are the only provider of retail test kits in the United States which do not require the use of any bodily fluids or samples, thereby providing users with a non-confrontational solution which doesn't even require the involvement of a suspected user.

We have also developed tests for drug precursors, chemical substances which can be used to manufacture illicit drugs. Our tests currently can identify the presence of acetic anhydride, ephedrine, pseudoephedrine and methamphetamine, all common drug precursors. We have also developed detectors for synthetic drugs, also known as designer drugs.

Explosive Detector Kits

The Company also manufactures explosive detector kits targeted for use by law enforcement and security and safety professionals that offer significant features. Advantages include:

- The kit employs safe methodology which enables a user to administer the test while avoiding physical contact with the suspicious substance.
- The test is capable of detecting a broad range of the well-known types of military, commercial and the homemade explosives including TNT/PETN, RDX/Nitrate, Urea Nitrate, Ammonium Nitrate, TATP/HMTD/Peroxide and Chlorate/Bromate.
- Our latest TATP/HMTD/Peroxide detector has shown a high degree of reliability and consistently did not produce false positives. Also approved by some top worldwide laboratories.
- Our explosives detectors deploy chemicals with at least 3 years of chemical stability. The combination of long shelf-life and our very competitive pricing providing users with an extremely cost-effective product.
- Durable, easy to use, self-contained plastic packaging enables users to apply our tests in a wide variety of military and civilian field operations and make them particularly attractive solutions for airport security.
- Our detectors are extremely sensitive and can identify the presence of even trace amounts of explosive materials.
- The company has a unique Explosive General Screening to identify 21 types of explosives in one kit.

AeroChamber (Portable Sniffer)

In addition to our detection and ballistic kits, we also offer a revolutionary Sniff and Know product, a sniffer device which quickly and effectively can collect particles from large surfaces. Our product collects both visible samples and invisible granules measurable only in nanograms.

Sniff and Know can be used with both our drug and explosive detection kits and we believe it has significant market potential for use by law enforcement agencies, ports and border crossings, shipping hubs and in the private security and safety sector. Since Sniff and Know is used with our detection kits, we anticipate that an increase in sales creates the potential for significant order volume for the kits necessary to use the device. Please link to read more about our unique technology:

www.identa-corp.com/resources/videos.

Ballistics

Law enforcement officials and private investigators routinely use ballistic information in connection with investigations involving firearms. The identification of bullet-holes and of marks produced by projectiles has been shown to provide crucial information. Bullet-holes are usually characterized by the presence of metals, primarily lead and copper originating from the bullet's outer surfaces, in the perimeters of these holes. Often, investigators submit samples for laboratory testing since visual examination of bullet hole

morphology at the scene of an incident frequently leads to erroneous or incomplete conclusions. Waiting for results can cause significant delay which can hinder an investigation.

Our IDenta BTK kit rapidly and reliably identifies suspected bullet-holes in the field, enabling investigators to instantly act on and pursue leads. We are not aware of competing products with similar capabilities and we accordingly believe that there exist significant opportunities to market our kit to the law enforcement and security industries.

Markets

The market for drug detection products falls into four broad categories:

- Government Agencies and Public Institutions, which includes police and sheriff's offices, customs service, coast guard, postal services, the federal drug enforcement agency, armed forces, prisons and probation departments, schools, air traffic control centers, and drug rehabilitation centers.
- Industry, which includes industrial security services, manufacturing industries, food processing industries, pharmaceutical houses, transportation, shipping, passenger and freight airlines, testing of pilots and cargo service personnel, sports teams, and hospital emergency rooms.
- Analytical, which includes forensic and other laboratories; and
- Consumers, including parents, counselors, school personnel and businesses.

The market for our explosives detectors and ballistics kits falls into three categories:

- Government Agencies and Public Institutions, which includes police and sheriff's offices, customs service, Coast Guard, postal services, armed forces, prisons and probation departments, air traffic control centers.
- Industry, which includes industrial security services, transportation, shipping, passenger and cargo airlines.
- Analytical, which includes forensic and other laboratories.

Geographic Region and Distribution

The Company distributes its products through several methods and is exploring new distribution methods and channels. The Company uses distributors, representatives, and agents, including those specializing in government procurement contracts.

The Company sells to consumers through a large national drugstore chain which carries its drug detection kits and the internet.

The Company currently sells, or reasonably expects to sell in the foreseeable future, its products to law enforcement organizations in the following countries Indonesia, Argentina, Poland, France, USA, Spain,

India, the United Kingdom, Ghana, Nigeria, Australia, Russia, Israel, Canada, Germany, Italy and Portugal. The Company also sells to retail markets in the United States, Italy and South Africa. The Company is also actively exploring opportunities in Brazil, Mexico, Panama, Colombia, Ecuador, and Taiwan.

B. Distribution Methods of the Products

The world illegal drug trade is estimated at approximately one trillion dollars per year with wholesale annual drug sales in the US alone amounting to up to 300 billion dollars. Over 1.5 million people are arrested for drug offenses in the US each year, with many millions more arrested worldwide.

Approximately 25% of all drugs related arrests occur in the United States and United States federal and state authorities' budget more than \$50 billion dollars toward the war on drugs annually. The budget growth rate has increased by approximately 9% per year during recent years.

The Company develops and manufactures advanced forensics products primarily designed for use by law enforcement agencies and security personnel around the world. In addition, the Company develops and manufactures forensics products, specifically a line of drug detection products, for the wider drug detection "Retail" market. Retail customers include schools, corporations, employers, security companies, and concerned parents.

C. Status of any Publicly Announced New Product

The Company launched new websites and line of products for the consumer markets.

Brand 1: Touch&Know – Single use test to identify many types of drugs: www.touch-know.com

Brand 2: Swipper – Pack of single use products based on different price strategy: www.getswipper.com

- The company developed a new test kit to identify CBD as a result of high demand in the government sector.
- The company is working to add and develop more products under the Forensics' world sector.

D. Competitive Business Conditions

There are a number of competitors in the world, each of them has its own uniqueness.

The Company is able to compete with each competitor as a result of launching a pricing strategy model based on customers' demand. We are the only company in the world that can offer a couple different method of products based on the cutting-edge technology that can fit to any budget of the users.

E. Sources and Availability of Raw Materials

The company has a number of suppliers around the world in favor of the raw materials required in the plastic and chemical fields.

F. Dependence on One or a Few Major Customers

The company has several significant clients in Europe, USA and far east. Some of them are major customers and some of them not.

G. Patents & Trademarks

The company has a couple patents: EP/0983514B1, US/7,829,019, US/6,133,040, US/7,374,946.

The company has a couple registered trademarks: Touch&Know, Swipper.

The company has a couple trademarks: Sniff&Know, AeroChamber, Cusper, Smart-Tip, Dropper, Tanker, SmartX1, SmartX2, Trigger.

H. The Need for Any Government Approval of Principal Products

Products are required for approval from a government central laboratory in each country that we are looking to sell. The company's products have been approved in more than 15 countries current today and meeting the highest demand in each country.

Item 10. The Nature and Extent of the Issuer's Facilities.

The Company currently leases a facility located at 120 Bethlehem Road in Jerusalem, Israel for production. The facility is comprised of approximately 550 square meters and contains the Company's executive offices, research and development facility, and manufacturing plant. The Company's lease expires on December 31, 2028 with an option to extend. The Company also owns manufacturing and office equipment located at the facility. Equipment includes all products manufacturing, plastic molds and other machinery used for the manufacture and packaging of our products. The company has a new office in Washington DC area and a front warehouse in New Jersey for quick delivery of products for the USA market.

Part D: Management Structure and Financial Information

Item 11. The name of the CEO, Members of the Board of Directors and Control Persons.

A. Officers and Directors

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer /Director/Owner of more than 5%)	Business Address (City/State)	Number of Shares Owned	Share Type/Class	Ownership Percentage of Class Outstanding
Amichai Glattstein	Officer & Director	Jerusalem, Israel	164,998	Common	4.07%
Nachum Wissmann	Director	Jerusalem, Israel	84,261	Common	2.08%
Barry R. Alter	Director	Florida, USA	113,750	Common	2.81%
Yirat Lehrer	Director	Jerusalem, Israel	0	N/A	N/A
Baruch Glattstein	CTO	Jerusalem, Israel	157,500	Common	3.89%

B. Legal/Disciplinary History

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses): N/A
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities: N/A
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding, or judgment has not been reversed, suspended, or vacated: N/A
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities: N/A

C. Disclosure of Family Relationships

There is no individual who holds alone more than 5 percent of the company.

D. Disclosure of Related Party Transactions

Describe any transaction during the issuer's last two full fiscal years and the current fiscal year or any currently proposed transaction, involving the issuer, in which (i) the amount involved exceeds the lesser of \$120,000 or one percent of the average of the issuer's total assets at year-end for its last three fiscal years and (ii) any related person had or will have a direct or indirect material interest. Disclose the following information regarding the transaction:

1. The name of the related person and the basis on which the person is related to the issuer:
N/A
2. The related person's interest in the transaction:
N/A
3. The approximate dollar value involved in the transaction (in the case of indebtedness, disclose the largest aggregate amount of principal outstanding during the time period for which disclosure is required, the amount thereof outstanding as of the latest practicable date, the amount of principal and interest paid during the time period for which disclosure is required, and the rate or amount of interest payable on the indebtedness):
N/A
4. The approximate dollar value of the related person's interest in the transaction:
N/A
5. Any other information regarding the transaction or the related person in the context of the transaction that is material to investors in light of the circumstances of the particular transaction.
N/A

E. Disclosure of Conflicts of Interest

1. Describe any conflicts of interest. Describe the circumstances, parties involved and mitigating factors for any executive officer or director with competing professional or personal interests.name of the related person and the basis on which the person is related to the issuer:
N/A

Item 12. Financial Information for the Issuer's Most Recent Fiscal Period



REPORT OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and Board of Directors of
IDENTA CORP

Opinion on the Financial Statements

We have audited the accompanying balance sheets of IDENTA CORP ("the Company") as of December 31, 2023 and 2022 and the related statements of operations, changes in stockholders' deficit and cash flows, for each of the years in the period ended December 31, 2023, and the related notes and schedules (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with generally accepted accounting principles in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Going Concern

Since the company has accumulated considerable operating losses we considered whether a Going Concern warning would be required. However since the company has a considerable excess of current assets over liabilities and has been showing a net profit for a considerable period it is our opinion that no such warning would be required

/s/Weinstein International C.P.A. (PCAOB ID #6629)

We have served as the Company's auditor since 2019.

Tel Aviv, Israel
March 05, 2024



IDENTA CORP
Consolidated Balance Sheets

		As of December 31	
		2023	2022
	Notes	\$	
ASSETS			
<u>Curret Assets</u>			
Cash and cash equivalents		264,294	* 433,610
Accounts receivable	3	328,084	154,482
Other receivables	4	20,996	16,889
Inventories		430,020	449,518
<i>Total Current Assets</i>		<u>1,043,394</u>	<u>1,054,499</u>
<u>Non- current assets</u>			
Finance Lease Asset	5	294,760	372,597
Fixed Assets, Net	6	191,121	196,528
<i>Total Non Current Assets</i>		<u>485,881</u>	<u>569,125</u>
TOTAL ASSETS		<u>1,529,275</u>	<u>1,623,624</u>

* re-sorted.

The accompanying notes are an integral part of that financial statements.

IDENTA CORP
Consolidated Balance Sheets

		As of December 31	
		2023	2022
	Notes		\$
<u>Current Liabilities</u>			
Short-term credit		60,679	* 64,709
Accounts payable	7	96,174	88,643
Other payables	8	62,343	89,192
<i>Total Current Liabilities</i>		<u>219,196</u>	<u>242,544</u>
<u>Non Current Liabilities</u>			
Loans from shareholders		300,826	* 310,058
Other payables - related parties	9	127,350	* 137,622
Operating Lease Liability	5	296,511	372,597
Employee benefit obligations	10	69,276	101,174
<i>Total Non Current Liabilities</i>		<u>793,963</u>	<u>921,451</u>
Total Liabilities		<u>1,013,159</u>	<u>1,163,995</u>
<u>Stockholders' equity</u>			
Common stock, \$0.001 par value; 16,400,000,000 share authorized; 4,045,589			
shares issued and outstanding at December 31, 2023 and 2022.			
	11	4,046	4,046
Paid in capital		3,999,295	3,999,295
Treasury Stock		(28,935)	(28,935)
Capital fund from translation differences		21,206	(20,637)
Stock options		9,128	9,128
Accumulated deficit		(3,488,624)	(3,503,268)
Total stockholders' equity		<u>516,116</u>	<u>459,629</u>
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		<u>1,529,275</u>	<u>1,623,624</u>

*re-sorted.

Amichai
CEO

February 13, 2024

The accompanying notes are an integral part of that financial statements.

IDENTA CORP
Consolidated Statement of Comprehensive Income

		Year ended December 31	
		2023	2022
		\$	
Revenues		1,051,590	1,338,754
Grants income		49,714	139,628
Research and development expenses		(2,022)	(208)
Cost of sales	13	(386,593)	(355,153)
Gross profit		712,689	1,123,021
Administrative and general expenses		(714,188)	(997,705)
Profit (Loss) before finance income		(1,499)	125,316
Finance income, net	14	19,583	37,846
Profit before taxation		18,084	163,162
Income tax expense		(3,440)	(451)
Net profit		14,644	162,711
Net profit per common share - basic and diluted			
Net profit per share attributable to common stockholders		0.003	0.04
Weighted-average number of common shares outstanding		4,045,589	4,045,589
Weighted-average common share outstanding		4,715,589	4,715,589

The accompanying notes are an integral part of that financial statements.

IDENTA CORP
Consolidated Statements of Stockholders' Equity

Common Stock								
		Amount	Paid in capital	Stock options	capital fund from translation differences	Treasury Stock	Accumulated equity	Total shareholders' equity
	Shares				\$			
Balance of January 1, 2021	4,045,589	4,046	3,999,295	9,128	112,459	(28,935)	(3,665,979)	430,014
Profit (Loss) for the year	-	-	-	-	(133,096)	-	162,711	29,615
Balance of December 31, 2022	4,045,589	4,046	3,999,295	9,128	(20,637)	(28,935)	(3,503,268)	459,629
Profit for the year	-	-	-	-	41,843	-	14,644	56,487
Balance of December 31, 2023	4,045,589	4,046	3,999,295	9,128	21,206	(28,935)	(3,488,624)	516,116

The accompanying notes are an integral part of that financial statements.

IDENTA CORP
Consolidated Statement of Cash Flows

	Year ended December 31	
	2023	2022
	\$	
<u>Cash flows from operating activities</u>		
Net profit	14,644	162,711
Adjustments for non-cash income and expenses		
Depreciation	13,561	21,450
Provision for severance pay	(31,898)	4,383
Capital fund from translation differences	41,843	(133,096)
Capitalization expenses for lease	14,460	-
Rate differences due to lease	(9,343)	-
Decrease in non-cash rent	(3,366)	-
	<u>25,257</u>	<u>(107,263)</u>
Changes in operating assets and liabilities		
Decrease (Increase) in accounts receivable	(173,602)	59,483
Decrease (Increase) in other receivables	(4,107)	26,102
Decrease (Increase) in inventory	19,498	(33,662)
Increase (Decrease) in accounts payable	7,531	(47,082)
Increase (Decrease) in other payables	(26,849)	34,023
	<u>(177,529)</u>	<u>38,864</u>
Net cash earned (used) in operating activities	<u>(137,628)</u>	<u>94,312</u>
<u>Cash flows from investing activities</u>		
Acquisition of fixed assets	(14,343)	(32,748)
Adjustments arising from the translation of financial statements of foreign operations	6,189	24,137
Net cash used in investing activities	<u>(8,154)</u>	<u>(8,611)</u>
<u>Cash flows from financing activities</u>		
Proceeds from (Repayment of) short term loan from banks	(4,030)	1,702
Repayment of loan with shareholders	(9,232)	*(40,777)
Repayment of loan with related parties	(10,272)	*(23,173)
Net cash used in financing activities	<u>(23,534)</u>	<u>(62,248)</u>
Increase (Decrease) in cash and cash equivalents	(169,316)	23,453
Cash and cash equivalents at the beginning of the year	433,610	* 410,157
Cash and cash equivalents at the end of the year	<u>264,294</u>	<u>433,610</u>

*re-sorted.

The accompanying notes are an integral part of that financial statements.

IDENTA CORP

Notes to the Consolidated Financial Statements

Note 1 - Nature of business of presentation

IDENTA CORP (the "Company") is a Florida Corporation incorporated on June 3, 1997 as Future products VI corp until July 2000 and was known also as Bouy Club, Inc. until January 2002. The Company is a sole shareholder of Identa Ltd, an Israeli limited company. The operation of the company is through its subsidiary, which develops products to test for the presence of illegal drugs for the law enforcements industry.

Basis of Presentation

The Company maintains its accounting records on an accrual basis in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").

These financial statements are presented in US dollars.

Fiscal Year End

The Corporation has adopted a fiscal year end of December 31.

On October 7, 2023, a surprise attack began on the State of Israel that led to the opening The "Iron Swords" war that is still going on these days. War has macro consequences A broad economy continues to influence and may continue to influence directly and indirectly on the activities of many companies operating in various business sectors. The main effects of the war on the entity include, among others, disruptions in production and in the supply chain and lack of personnel availability.

Note 2 - Summary of significant accounting policies

The principal accounting policies are set out below, these policies have been consistently applied to the period presented, unless otherwise stated:

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts or revenues and expenses during the reporting period. Actual results could differ from those estimates.

Customers Concentration

Revenues from one customer represent approximately EURO 275,544 and EURO 513,011 (about \$303,511 and \$527,229) of the company's revenue for the year ended December 31, 2023 and 2022, respectfully.

Revenues from another customer represent approximately \$116,607 and \$201,481 of the company's revenue for the year ended December 31, 2023 and 2022, respectfully.

Revenues from another customer represent approximately \$137,031 and \$127,068 of the company's revenue for the year ended December 31, 2023 and 2022, respectfully.

Those customers and this revenue is part of a long term contracts for product supply over the existence of the contracts. The end user of our products for those contracts are governmental agencies.

Principles of Consolidation

The consolidated financial statements include the accounts of IDENTA CORP and its subsidiaries. Intercompany transactions and balances have been eliminated. Equity investments through which we are able to exercise significant influence over but do not control the investee and are not the primary beneficiary of the investee's activities are accounted for using the equity method. Investments through which we are not able to exercise significant influence over the investee and which do not have readily determinable fair values are accounted for under the cost method.

Foreign Currencies

The consolidated financial statements are presented in U.S. Dollars, which is the Company's functional currency and presentation currency. The financial statements of entities that use a functional currency other than the U.S. Dollar are translated into U.S. Dollars. Assets and liabilities are translated using the exchange rate on the respective balance sheet

IDENTA CORP

Notes to the Consolidated Financial Statements

Note 2 - Summary of significant accounting policies (Cont.)

dates. Items in the income statement and cash flow statement are translated into U.S. Dollars using the average rates of exchange for the periods involved. The resulting translation adjustments are recorded as a separate component of other comprehensive income ("OCI") within stockholders' equity.

The functional currency of foreign entities is generally the local currency unless the primary economic environment requires the use of another currency. Gains or losses arising from the translation or settlement of foreign-currency-denominated monetary assets and liabilities into the functional currency are recognized in the income in the period in which they arise.

New Israeli Shekel ("NIS") amounts as of December 31, 2023 have been translated into U.S. Dollars at the representative rate of exchange on December 31, 2023 (USD 1 = NIS 3.627). Revenue and expenses have been translated into U.S. Dollars at the average rate of exchange on for the year ended on December 31, 2023 (USD 1 = NIS 3.6867).

Cash and cash equivalents

Cash and equivalents include investments with initial maturities of three months or less. The Company maintains its cash balances at credit-worthy financial institutions that are insured by the Federal Deposit Insurance Corporation ("FDIC") up to \$250,000.

Accounts Receivable

The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Based on historical collection activity, the Company had specific provisions for bad debts in December 31, 2023 and 2022.

Inventories

Inventories are stated at average cost, subject to the lower of cost or market. Cost includes materials, labor, and manufacturing overhead related to the purchase and production of inventories. We regularly review inventory quantities on hand, future purchase commitments with our suppliers, and the estimated utility of our inventory. If our review indicates a reduction in utility below carrying value, we reduce our inventory to a new cost basis through a charge to cost of revenue. The determination of market value and the estimated volume of demand used in the lower of cost or market analysis require significant judgment.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using shorter of useful live of the property or the unit of depletion method. For shorter-lived assets the straight-line method over estimated lives ranging from 3 to 10 years is used as follows:

Furniture	6-7 years
Capital Improvements	10 years
Computers and Electronic Equipments	3-10 years

Impairment Long-Lived Assets

IDENTA CORP

Notes to the Consolidated Financial Statements

Note 2 - Summary of significant accounting policies (Cont.)

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses the impairment of long-lived assets (including identifiable intangible assets) annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method. Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets. The Company estimates the future cash flows of the long-lived assets using current and long-term financial forecasts. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If this were the case, an impairment loss would be recognized. The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses are carried at amortized cost and represent liabilities for goods and services provided to the Company prior to the end of the financial year that are unpaid and arise when the Company becomes obliged to make future payments in respect of the purchase of these goods and services.

Earnings per Share

The Company computes net profit or loss per share in accordance with ASC 260, "Earnings Per Share" ASC 260 requires presentation of both basic and diluted earnings per share ("EPS") on the face of the income statement. Basic EPS is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all potential dilutive common shares, which comprise options granted to employees. As December 31, 2023, the Company had 670,000 options that could dilute the shares.

Income Taxes

Income taxes are accounted for in accordance with ASC Topic 740, "Income Taxes." Under the asset and liability method, deferred tax assets and liabilities are recognized for the future consequences of differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases (temporary differences). Deferred tax assets and liabilities are measured using tax rates expected to apply to taxable income in the years in which those temporary differences are recovered or settled. Valuation allowances for deferred tax assets are established when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Revenue Recognition

The Company recognizes revenue when all of the following have occurred: persuasive evidence of an agreement with the customer exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable and collectability of the selling price is reasonably assured.

Cost of Sales

Cost of sales includes all of the costs to manufacture the Company's products. For products manufactured in the Company's own facilities, such costs include raw materials and supplies, direct labour and factory overhead. For products manufactured for the Company by third-party contractors, such cost represents the amounts invoiced by the contractors.

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring

IDENTA CORP
Notes to the Consolidated Financial Statements

Note 2 - Summary of significant accounting policies (Cont.)

or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

The following are the hierarchical levels of inputs to measure fair value:

- Level 1: Quoted prices in active markets for identical instruments;
- Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments);
- Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments).

Note 3 - Accounts receivable

	As of December 31	
	2023	2022
	\$	
Account Receivable	331,697	158,370
Less - provision for doubtful debts	(3,613)	(3,888)
	<u>328,084</u>	<u>154,482</u>

Note 4 - Other receivables

	As of December 31	
	2023	2022
	\$	
Advance payments to suppliers	12,261	-
Prepaid expenses	1,136	1,168
Institutions	7,599	15,721
	<u>20,996</u>	<u>16,889</u>

Note 5 - Finance Lease Asset

The Company entered into a lease agreement on November 11, 2021, for its offices, the manufacturing plant and its warehouses in Israel, through December 2027. Base monthly rental payments, excluding common area maintenance charges, are \$8,050. As of December 31, 2023, we have an operating lease asset balance of \$294,760 and an operating lease liability balance of \$296,511 recorded in accordance with ASC 842, Leases (ASC "842").

IDENTA CORP
Notes to the Consolidated Financial Statements

Note 6 - Fixed Assets, Net

	Computers and electronic equipment	Furniture	Capital Improvements	Total
	\$			
<u>Cost</u>				
Balance as at January 1, 2023	21,962	271,266	21,599	314,827
Current year	1,387	12,702	254	14,343
Adjustments arising from the translation of financial statements of foreign operations	(631)	(9,155)	(639)	(10,425)
Balance as at December 31, 2023	<u>22,718</u>	<u>274,813</u>	<u>21,214</u>	<u>318,745</u>
<u>Accumulated Depreciation</u>				
Balance as at January 1, 2023	17,861	78,864	21,574	118,299
Current year	1,980	11,459	122	13,561
Adjustments arising from the translation of financial statements of foreign operations	(640)	(2,858)	(738)	(4,236)
Balance as at December 31, 2023	<u>19,201</u>	<u>87,465</u>	<u>20,958</u>	<u>127,624</u>
Fixed Assets, Net as at December 31, 2023	<u>3,517</u>	<u>187,348</u>	<u>256</u>	<u>191,121</u>
Fixed Assets, Net as at December 31, 2022	<u>4,101</u>	<u>192,402</u>	<u>25</u>	<u>196,528</u>

Note 7 - Accounts payable

	As of December 31	
	2023	2022
	\$	
Trade creditors	90,504	84,978
Outstanding checks	1,890	1,295
credit cards	3,780	2,370
	<u>96,174</u>	<u>88,643</u>

Note 8 - Other payables

	As of December 31	
	2023	2022
	\$	
Institutions	-	16,267
Accrued expenses	18,205	30,264
Employees	44,138	42,661
	<u>62,343</u>	<u>89,192</u>

IDENTA CORP
Notes to the Consolidated Financial Statements

Note 9 - Related parties

Details of transaction between the Company and related parties are disclosed below:

The following entities have been identified as related parties:

Amichai Glattstein - CEO Director and greater than 10% stockholder (held directly and/or by immediate family)
Mishaël Shpizer - COO Operational Manager
Frank Gottesman - (VP' Client Services & Operations)
Baruch Glattstein - CTO Technology Manager

The following balances exist with related parties:

	<u>As of December 31</u>	
	<u>2023</u>	<u>2022</u>
	\$	
Loan from related parties	<u>127,350</u>	<u>* 137,622</u>

From time to time, the directors and stockholder of the Company provides advances to the Company for its working capital purposes. These advances bear no interest and are due on demand.

The above loan is unsecured, bears no interest and has no set terms of repayment.
This loan is repayable on demand.

The difference is due to exchange rate differences.

* re-sorted.

Income statement

The following transactions were carried out with related parties:

	<u>As of December 31</u>	
	<u>2023</u>	<u>2022</u>
	\$	
Director comensation	<u>252,923</u>	<u>252,462</u>

Note 10 - Employee benefit obligations

Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The following principal plans relate to the employees in Israel:

The Company's liability for severance pay for its Israeli employees is calculated pursuant to Israeli severance pay law based on the most recent salary of the employee multiplied by the number of years of employment, as of the balance sheet date. Employees are entitled to one month's salary for each year of employment, or a portion thereof. The Company's liability for all of its Israeli employees is partially provided for by monthly deposits in insurance policies and the remainder by an accrual in the financial statements. The value of these policies is recorded as an asset in the Company's balance sheet.

The deposited funds include profits/loss accumulated up to the balance sheet date. The value of the deposited funds is based on current redemption value of these policies. Withdrawals from the funds may be made only upon termination of employment.

IDENTA CORP
Notes to the Consolidated Financial Statements

Note 11 - Capital Stock

Common stock

On July 1, 2016 the Company issued 340,000,000 shares of common stock. Shares were issued to lenders and officers of the company for service equivalent- the price evaluate is \$102,000.

On November 1, 2016 the Company issued 150,000,000 shares of common stock. Shares were issued to officers of the company for service equivalent- the price evaluate is \$75,000.

On November 21, 2016 the Company issued 100,000,000 shares of common stock. Shares were converted instead of a loan of \$100,000.

On November 30, 2016 the Company issued 1,654,000,000 shares of common stock. Shares were issued to investors at a price of \$ 0.00035 per share for cash, for \$578,000.

On December 1, 2016 the Company issued 150,480,000 shares of common stock. Shares were issued due to anti-diluted agreement with investors.

On February 28, 2017 the Company issued 137,610,000 shares of common stock. Shares were issued due to cancelling the anti-diluted agreement with investors.

On March 23, 2017 the Company issued 50,000,000 shares of common stock. Shares were issued to investors at a price of \$ 0.000367 per share for cash, for \$18,484.

On May 15, 2017 the Company granted an option to purchase 48,000 shares in a price of \$1.6 per share (in the event of share consolidation, there shall be an adjustment). The options will vest on a monthly basis over a period of one year, amounting to 16 million shares per month (in the event of share consolidation, there shall be an adjustment). The options will expire on May 15, 2027 or 6 months following the date of the termination of services.

The vendor gave services for 2 months.

Options were issued to vendors of the company for service equivalent- the price evaluate is \$9,128.

On June 20, 2017 the Company came to effect a reverse share split of its shares at a ratio of 1-for-4,000. As a result of the reverse share split, the Company's issued and outstanding ordinary shares will decrease to 4,024,929 ordinary shares, post-split.

On November 7, 2017 the Company issued 20,000 shares of common stock. Shares were issued to investors at a price of \$ 1.026 per share for cash, for \$20,520.

On February 1, 2020, the Company granted 80,000 stock options to the Chairman of the Company, exercisable at \$1 per share and expire three years after vesting date. The options vest monthly for the next 12 months starting at February 28, 2020. Employee Stock Option (ESO)

On April 4, 2022, the company granted its employees 670,000 options to purchase the company's shares, valid for five years. Each option gives the right to purchase one share for a total of 50 cents, So if all the options are exercised, \$335,000 will be added to the equity.

The option will expire on April 4, 2027.

IDENTA CORP
Notes to the Consolidated Financial Statements

Note 12 - Income taxes

The Company provided a valuation for previous years, the Company did not record an allowance for tax payment or tax benefit. Due to new regulation, the Company does not carry forward all losses it accumulated in the past, and therefore the Company does not record future tax benefit. The Company expects to carry losses to offset the profit of the year ended December 31, 2023.

The Company did not identify any material uncertain tax positions. The Company did not recognize any interest or penalties for unrecognized tax benefits.

The federal income tax returns of the Company are subject to examination by the IRS, generally for three years after they are filed.

Note 13 - Cost of sales

	Year ended December 31	
	2023	2022
	\$	
Material consumption	277,214	256,379
Other costs	109,379	98,774
	<u>386,593</u>	<u>355,153</u>

Note 14 - Finance income, net

	Year ended December 31	
	2023	2022
	\$	
<u>Finance costs</u>		
Bank institutions	25,482	14,946
<u>Finance income</u>		
Interest from institutions	144	165
Exchange rate differences	44,921	52,627
	<u>45,065</u>	<u>52,792</u>
	<u>19,583</u>	<u>37,846</u>

Note 15 - Commitments and contingencies

During 2016 the company received loans from shareholders. The company has disagreement with the lenders regarding to the interest obligation. The company expects this issue to be resolved.

Note 16 - Subsequent events

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report.

Item 13. Similar Financial Information for Such Part of the Two Preceding Fiscal Years as the Issuer or its Predecessor has been in Existence

All Financial information available at: www.otcm Markets.com/stock/IDTA/financials

Item 14. Beneficial Owners

1. Provide a list of the name, address and shareholdings of all persons beneficially owning more than five percent (5%) of any class of the issuer's equity securities.

N/A

Item 15. Outside Providers that Advise the Issuer on Matters Relating to Operations, Business Development and Disclosure

1. Investment Bank

N/A

2. Promotor

N/A

3. Security Counsel

Name: Steve Korngold

Firm: SRK Law Officers

Address 1: Oppenheimer 7, Rehovot, Israel

Phone: +972.8.9360998

Email: steve@kronengold.com

4. Accountant or Auditor

Name: Idan Weinstein

Firm: Weinstein International CPA

Address 1: 16 Homa Umigdal, Tel-Aviv, Israel

Phone: +972.77.7386663

Email: e@dwacc.com

Licensing & Qualification: PCAOB

5. Public Relations Consulting

Internal: pr@identa-corp.com

6. Investor Relations Consulting

N/A

7. Tax Consulting

Name: Philip Stein and Associates

Firm: Tax Consultant

Address: Kiryat Hamada 11, Jerusalem 9777611, Israel

Phone: +1-866-995-1040, Email: info@pstein.com

Item 16. Management's Discussion and Analysis of Plan of Operation

A. Plan of Operation

1. The company is profitable and exists based on its own sales. If there will be fundraising in the near or far future, it will be for the purpose of growing the company.
2. There are a number of new drugs from the recent times that are starting to spread around the world and the company is working on developments for them. In addition, the company develops additional product models to enter new markets and access tenders at varied prices.
3. The company invested a lot of money in the last year to upgrade the production line and to enlarge the automation machines in the manufacturing floor.
4. The company, if necessary, will make changes in the number of its employees.

B. Management's Discussion and Analysis of Financial Condition and Results of Operations

1. Any known trends, events or uncertainties that have or are reasonably likely to have a material impact on the issuer's short-term or long-term liquidity:
No
2. Internal and external sources of liquidity:
The company is profitable and exists from its sales.
3. Any material commitments for capital expenditures and the expected sources of funds for such expenditures:
No
4. Any known trends, events or uncertainties that have had or that are reasonably expected to have a material impact on the net sales or revenues or income from continuing operations:
No
5. Any significant elements of income or loss that do not arise from the issuer's continuing operations:
No
6. The causes for any material changes from period to period in one or more-line items of the issuer's financial statements:
No
7. Any seasonal aspects that had a material effect on the financial condition or results of operation:
No
8. Interim Periods:
The company became a profitable company in 2018 and keep going based on its own sales. The company has no debts to the banks and no unrecognized expense is expected that could affect the company's level of liquidity and continuity.

C. Off-Balance Sheet Arrangements

1. The nature and business purpose to the issuer of such off-balance sheet arrangements:
The company develops, manufactures and sells test kits to identify suspicious materials in order to be part of the global fight against the drug and explosives problem. The company's ultimate goal is a better and safer world.
2. The importance to the issuer of such off-balance sheet arrangements in respect of its liquidity, capital resources, market risk support, credit risk support or other benefits:
The company has new management since the beginning of 2017. The ultimate objective was that the company will be profitable and will exist from the sales of its own products and developments in the present and future and will maintain constant liquidity.
3. The amounts of revenues, expenses and cash flows of the issuer arising from such arrangements; the nature and amounts of any interests retained, securities issued and other indebtedness incurred by the issuer in connection with such arrangements; and the nature and amounts of any other obligations or liabilities (including contingent obligations or liabilities) of the issuer arising from such arrangements that are or are reasonably likely to become material and the triggering events or circumstances that could cause them to arise:
The company does not take risks that can threaten its continued existence. Under the company's new management, there is strict monitoring of the company's expenses and cash flow in order to maintain the company's profitability and to maintain the interest of its shareholders.
4. Any known event, demand, commitment, trend or uncertainty that will result in or is reasonably likely to result in the termination, or material reduction in availability to the issuer, of its off-balance sheet arrangements that provide material benefits to it, and the course of action that the issuer has taken or proposes to take in response to any such circumstances:
The company is careful not to take risks that may harm its current and future operations.
5. Any obligation under a guaranteed contract that has any of the characteristics identified in paragraph 3 of FASB Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others (November 2002) ("FIN 45"), as may be modified or supplemented, and that is not excluded from the initial recognition and measurement provisions of FIN 45 pursuant to paragraphs 6 or 7 of that Interpretation:
No
6. A retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets:
No
7. Any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument, except that it is both indexed to the issuer's own stock and classified

in stockholders' equity in the issuer's statement of financial position, and therefore excluded from the scope of FASB Statement of Financial Accounting Standards No. 133, Accounting for Derivative Instruments and Hedging Activities (June 1998), pursuant to paragraph 11(a) of that Statement, as may be modified or supplemented:

No

8. Any obligation, including a contingent obligation, arising out of a variable interest (as referenced in FASB Interpretation No. 46, Consolidation of Variable Interest Entities (January 2003), as may be modified or supplemented) in an unconsolidated entity that is held by, and material to, the issuer, where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with, the issuer:

No

Part E: Issuance History

Item 17. List of Securities Offerings and Shares Issued for Services in the Past Two Years

Date of Issuance	Security Type	Shares Issued	Class of Securities	Value of Shares Issued at Issuance	Individual / Entity Shares were issued to	Reason for share Issuance or Nature of Services Provided	Issuance Type	Exemption or Registration Type
April 1, 2022	Stock Option	300,000	Common Stock	\$0.50 per Option	Individual/ Baruch Glattstein	Company Program	Restricted	Exempt
April 1, 2022	Stock Option	240,000	Common Stock	\$0.50 per Option	Individual/ Amichai Glattstein	Company Program	Restricted	Exempt
April 1, 2022	Stock Option	60,000	Common Stock	\$0.50 per Option	Individual/ Zeev Lerer	Company Program	Restricted	Exempt
April 1, 2022	Stock Option	45,000	Common Stock	\$0.50 per Option	Individual/ Barry R. Alter	Company Program	Restricted	Exempt
April 1, 2022	Stock Option	25,000	Common Stock	\$0.50 per Option	Individual/ Nachum Wissmann	Company Program	Restricted	Exempt

Part F: Exhibits

Item 18. Material Contracts

1. Any contract to which directors, officers, promoters, voting trustees, security holders named in the disclosure statement, or the Designated Advisor for Disclosure are parties other than contracts involving only the purchase or sale of current assets having a determinable market price, at such market price:

N/A

2. Any contract upon which the issuer's business is substantially dependent, including but not limited to contracts with principal customers, principal suppliers, and franchise agreements:

N/A

3. Any contract for the purchase or sale of any property, plant or equipment for consideration exceeding 15 percent of such assets of the issuer:

N/A

4. Any material lease under which a part of the property described in the disclosure statement is held by the issuer:

N/A

5. Any management contract or any compensatory plan, contract or arrangement, including but not limited to plans relating to options, warrants or rights, pension, retirement or deferred compensation or bonus, incentive or profit sharing (or if not set forth in any formal document, a written description thereof) in which any director or any executive officer of the issuer participates shall be deemed material and shall be included; and any other management contract or any other compensatory plan, contract, or arrangement in which any other executive officer of the issuer participates shall be filed unless immaterial in amount or significance.

N/A

The following management contracts or compensatory plans need not be included:

6. Ordinary purchase and sales agency agreements:

N/A

7. Agreements with managers of stores in a chain organization or similar organization:

N/A

8. Contracts providing for labor or salesmen's bonuses or payments to a class of security holders, as such:

N/A

9. Any compensatory plan that is available to employees, officers or directors generally and provides for the same method of allocation of benefits between management and non-management participants:

N/A

Item 19. Articles of Incorporation and Bylaws

The bylaws of the company can be review in the following link:

<https://www.otcmarkets.com/stock/IDTA/disclosure>

Item 20. Purchases of Equity Securities by the Issuer and Affiliated Purchasers

In the following tabular format, provide the information specified in paragraph (B) of this Item 20 with respect to any purchase made by or on behalf of the issuer or any "Affiliated Purchaser" (as defined in paragraph (C) of this Item 20) of shares or other units of any class of the issuer's equity securities:

N/A

Item 21. Certifications

I, Amichai Glattstein, certify that:

1. I have reviewed this annual disclosure statement of IDenta Cop.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: March 28, 2024

Name: Amichai Glattstein

Title: Chief Executive Officer

By: /s/ Amichai Glattstein